Effects of Epoetin-α on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy*

Background: Erythropoietin corrects and prevents anemia and decreases the need for red blood cell (RBC) transfusions; its impact on quality of life (QOL) of cancer patients receiving chemotherapy is not clear. Patients and Methods: 399 patients with solid tumors and Hb level of ≤12 g/dl receiving chemotherapy were randomized to receive or not 10,000 IU epoetin-α thrice weekly. QOL was measured by the Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale and various subscales at baseline, at two months and at the end of the study. Results: Changes in the average QOL scores were similar in the two groups. The improvement in Hb levels was significantly higher for the epoetin-α group, with a decrease in transfusion requirements compared to the control group. Conclusion: Epoetin-α does not improve QOL of patients with solid tumors receiving chemotherapy as assessed using FACT-An scale and various subscales, despite improving Hb levels and reducing transfusion requirements.